Semaglutide (Ozempic, Wegovy) is the established GLP-1 standard. Retatrutide is the next generation — a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trial data shows retatrutide produces ~24% average weight loss vs ~15% for semaglutide. Here's the complete head-to-head comparison.
Retatrutide produces greater average weight loss than semaglutide, but has significantly less clinical evidence. Phase 2 data shows ~24% weight loss at 48 weeks vs ~15% for semaglutide at 68 weeks. The trade-off: semaglutide has FDA approval, long-term safety data, and cardiovascular outcome trials — retatrutide has only Phase 2 data and higher common side effect rates (particularly nausea). For researchers focused on maximum fat loss who are comfortable with Phase 2-level evidence, retatrutide is the more potent option. For researchers who need the most established safety profile, semaglutide remains the gold standard.
The key difference between retatrutide and semaglutide is the number of receptor pathways each medication works on. Semaglutide's active ingredient is a GLP-1 receptor agonist — it mimics the glucagon-like peptide-1 hormone to suppress appetite, slow gastric emptying, and stimulate insulin secretion in a glucose-dependent manner. This single-pathway mechanism produces ~15% average weight loss and meaningful blood sugar control.
Retatrutide adds two additional receptor pathways to the same GLP-1 foundation. The GIP (glucose-dependent insulinotropic polypeptide) receptor agonism improves fat metabolism and insulin sensitivity beyond what GLP-1 alone achieves. The glucagon receptor agonism — the most distinctive feature of retatrutide — increases thermogenesis and resting energy expenditure, creating a dual action that burns more calories even at rest. This triple mechanism is why retatrutide produces ~24% average weight loss in Phase 2 trials.
| Receptor | Semaglutide | Retatrutide | Effect |
|---|---|---|---|
| GLP-1R | ✓ Agonist | ✓ Agonist | Appetite suppression, gastric emptying, insulin secretion |
| GIPR | ✗ None | ✓ Agonist | Improved fat metabolism, enhanced insulin sensitivity |
| GcgR (Glucagon) | ✗ None | ✓ Agonist | Thermogenesis, increased resting energy expenditure |
| Feature | Semaglutide (Ozempic/Wegovy) | Retatrutide |
|---|---|---|
| Mechanism / active ingredient | GLP-1 receptor agonist | GLP-1 + GIP + Glucagon triple agonist |
| Average weight loss | ~15% (STEP 1, 68 wks) | ~24% (Phase 2, 48 wks) |
| Blood sugar control | Yes — FDA approved for T2D (Ozempic) | Yes — Phase 2 HbA1c data (not approved) |
| Thermogenic / dual action | No | Yes (glucagon receptor increases thermogenesis) |
| Visceral fat reduction | Moderate | Strongest studied to date |
| FDA approval status | Yes (Ozempic / Wegovy / Rybelsus) | Phase 3 — not yet approved |
| Cardiovascular outcome data | Yes (FLOW trial, SUSTAIN-6) | Not yet available |
| Common side effects (nausea) | 30–44% | 47–58% (higher, same class) |
| Long-term safety data | Extensive (5+ years) | Limited to Phase 2 duration |
| Half-life | ~7 days (weekly injection) | ~6 days (weekly injection) |
| Research grade available | Yes (Purgo Labs) | Yes (Purgo Labs) |
The most important consideration in the retatrutide vs semaglutide comparison is the depth of clinical evidence. Semaglutide has completed multiple Phase 3 trials (STEP 1–5, SUSTAIN series), has FDA approval for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy), and has long-term cardiovascular outcome data from the FLOW and SUSTAIN-6 trials. This represents years of research evidence across tens of thousands of participants.
Retatrutide has completed Phase 2 trials (NCT04881760) showing ~24% mean weight loss at 48 weeks — the highest weight loss ever recorded in a Phase 2 trial at the time of publication. Phase 3 trials are currently enrolling. This means retatrutide still in clinical trials for all indications, and long-term safety data beyond 48 weeks is not yet available.
Both compounds share the same class-level GI side effect profile. Nausea is the most common side effect for both, and both improve significantly with slow titration over 16–20 weeks. The key difference is frequency: retatrutide has higher rates of nausea (~47–58% at therapeutic doses) compared to semaglutide (~30–44%). This is attributed to the additional glucagon receptor agonism, which has direct GI effects.
| Side Effect | Semaglutide Rate | Retatrutide Rate |
|---|---|---|
| Nausea | 30–44% | 47–58% (higher) |
| Vomiting | 10–24% | 18–30% (higher) |
| Diarrhea | 20–30% | 20–28% (similar) |
| Constipation | 10–20% | 15–22% (slightly higher) |
| Injection site reactions | ~5% | ~5% (similar) |
| Hypoglycemia (T2D) | Low (glucose-dependent) | Low (glucose-dependent) |
Titration note: Both compounds require slow dose escalation to minimize GI side effects. A 16–20 week titration protocol significantly reduces nausea rates for both. See the retatrutide titration schedule for detailed dosing protocols.
Clinical trial data shows retatrutide produces greater average weight loss than semaglutide. Phase 2 trials showed retatrutide achieved ~24% mean body weight reduction at 48 weeks, compared to ~15% for semaglutide at 68 weeks in the STEP 1 trial. However, retatrutide has only Phase 2 data — semaglutide has extensive Phase 3 trials, FDA approval, and long-term cardiovascular outcome data (FLOW trial). For researchers evaluating which medication works better for maximum fat loss, retatrutide shows superior efficacy, but with less clinical evidence.
Semaglutide is a GLP-1 receptor agonist — its active ingredient targets a single receptor pathway to reduce appetite and slow gastric emptying. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The additional glucagon receptor agonism increases thermogenesis and energy expenditure, which is why retatrutide produces greater weight loss. The dual action of GIP + GLP-1 also improves insulin sensitivity beyond what GLP-1 alone achieves, which has implications for blood sugar control.
Both compounds share the same class-level GI side effect profile: nausea, vomiting, diarrhea, and constipation. Retatrutide has higher rates of nausea (~47–58% at therapeutic doses) compared to semaglutide (~30–44%). This is attributed to the additional glucagon receptor agonism. Both improve with slow titration over 16–20 weeks. Long-term side effect data for retatrutide is limited to Phase 2 duration; semaglutide has extensive long-term safety data from multiple Phase 3 trials.
Yes. Both compounds reduce blood sugar through GLP-1 receptor agonism, which stimulates insulin secretion in a glucose-dependent manner. Retatrutide's additional GIP receptor agonism further enhances insulin sensitivity. Phase 2 data showed retatrutide produced meaningful HbA1c reductions in participants with type 2 diabetes. However, semaglutide has FDA approval for glycemic control in type 2 diabetes (Ozempic) — retatrutide does not yet have this indication.
No. Retatrutide is currently in Phase 3 clinical trials. It is not FDA approved for any indication. Semaglutide (Ozempic, Wegovy, Rybelsus) is FDA approved for type 2 diabetes and chronic weight management. Research-grade retatrutide is available from verified suppliers like Purgo Labs for research purposes only.
Purgo Labs carries pharmaceutical-grade retatrutide and semaglutide with third-party COAs confirming ≥99% purity. All compounds are sold for research purposes only. Use code HEALTH for 15% off your first order.
Semaglutide achieves weight loss primarily through appetite suppression via GLP-1 receptor agonism — it reduces hunger signals and slows gastric emptying. Retatrutide adds two additional mechanisms: GIP receptor agonism (which improves fat metabolism and insulin sensitivity) and glucagon receptor agonism (which increases thermogenesis and resting energy expenditure). This triple mechanism is why retatrutide produces ~24% average weight loss vs ~15% for semaglutide — the medication works on three separate pathways simultaneously.
Purgo Labs provides pharmaceutical-grade retatrutide and semaglutide with third-party COAs confirming ≥99% purity. All compounds are sold for research purposes only. Use code HEALTH for 15% off your first order.
Shop Purgo LabsUse code HEALTH for 15% off · Research use only
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.